U.S.-based private equity firm Riordan, Lewis & Haden (RLH)’s sale of Avella Specialty Pharmacy commanded an about $325 million valuation.
The buyer is U.S.-based healthcare company UnitedHealth Group, which bought Avella through the pharmacy company OptumRx segment of its Optum subsidiary.
On 19 October 2017, Riordan, Lewis & Haden announced the final closing of RLH Investors IV, LP (fund 4) with total commitments of $510.6 million.
Fund 4 was oversubscribed, requiring an increase in the fund's original hard capitalization to accommodate strong investor interest. The new fund's size represented a more than 30 percent increase from the committed capital of RLH's prior fund.